secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytoDyn Inc. (CYDY)
CIK:        0001175680
Form:       8-K
Filed at:   2022-10-19T23:59:59+00:00
Accession:  0001558370-22-015082
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CytoDyn director Scott Kelly resigns; Stephen Simes appointed to board.
-----------------------------------------------------------------------

- Scott Kelly resigned as director effective Oct 13, 2022; remains CMO and Head of Business Development.
- Stephen Simes appointed director same day, filling Kelly's vacancy.
- Simes has 40+ years pharma experience, former CEO of BioSante and RestorGenex, director at several firms.
- Simes compensated per nonemployee director policies with cash retainers and stock options.
- No disclosable transactions or family relationships between Simes and other officers/directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175680/000155837022015082/0001558370-22-015082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175680/000155837022015082/cydy-20221013x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-015082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer